Dorsomorphin (Compound C): Precision AMPK and BMP Pathway Inhibition

Overview: Dorsomorphin’s Dual Inhibitory Principle

Dorsomorphin (Compound C) is a first-in-class ATP-competitive AMPK inhibitor and BMP signaling inhibitor, widely leveraged for interrogating metabolic and differentiation processes in eukaryotic models. With a Ki of 109 nM for AMPK and an IC₅₀ of 0.47 μM for BMP4-induced SMAD phosphorylation, Dorsomorphin delivers robust selectivity over related kinases, including PKA, PKC, and JAK3. Its ability to suppress downstream events—such as 80% inhibition of acetyl-CoA carboxylase (ACC) phosphorylation and autophagic proteolysis—positions it as a versatile tool for both fundamental and translational research.

Mechanistically, Dorsomorphin blocks AMPK-mediated energy sensing, impacting autophagy regulation, metabolic reprogramming, and iron metabolism modulation. Concurrently, it inhibits the BMP/Smad signaling pathway, which is critical in cell fate decisions, neural stem cell differentiation, and bone morphogenesis. The dual-pathway targeting enables researchers to unravel cross-talk between metabolic and differentiation signals, a capability highlighted in studies of cancer research and regenerative medicine.

Experimental Workflow: Protocol Enhancements and Practical Steps

1. Compound Preparation and Handling

• Solubilization: Dorsomorphin is insoluble in water and ethanol but dissolves in DMSO at ≥8.49 mg/mL with gentle warming and ultrasonic treatment. Prepare aliquots to avoid repeated freeze-thaw cycles.
• Storage: Store as a solid at -20°C. Use DMSO stock solutions promptly; avoid long-term storage in solution due to potential degradation.

2. Cell-Based Assays: AMPK and BMP Pathway Interrogation

• Inhibition of AMPK Activity in Hepatocytes: Treat hepatocyte cultures with Dorsomorphin at 4–40 μM. Monitor ACC phosphorylation by Western blot to confirm AMPK inhibition; expect up to 80% reduction in ACC phosphorylation at optimal doses (see published workflows for detailed protocols).
• Autophagy Regulation: Assess autophagic flux via LC3-II/I ratio or autophagosome formation using fluorescence microscopy. Dorsomorphin’s suppression of AMPK reduces autophagic proteolysis, enabling the study of energy stress responses.
• BMP4-Induced SMAD Phosphorylation Inhibition: In HeLa or stem cell models, apply Dorsomorphin at 1–10 μM to block SMAD 1/5/8 phosphorylation. Confirm pathway inhibition via phospho-SMAD immunoblotting.

3. In Vivo Studies: Iron Metabolism and Disease Modeling

• Animal Models: Administer Dorsomorphin at 10 mg/kg (i.p.). Measure hepatic hepcidin mRNA by qPCR and serum iron levels. Expect significant downregulation of hepcidin and increased iron, providing a platform for iron metabolism modulation studies.
• Zebrafish Dorsalization: Treat embryos with 10–50 μM to induce dorsalization phenotypes, a classical readout of BMP pathway inhibition.

Advanced Applications and Comparative Advantages

Translational Research in Cancer, Metabolism, and Neurobiology

Dorsomorphin’s dual inhibition unlocks unique experimental setups across cancer research, metabolic disease, and stem cell biology:

• Cancer Research: By disrupting the AMPK signaling pathway, Dorsomorphin helps define the metabolic plasticity of tumor cells and their reliance on autophagy during stress or chemotherapy.
• Stem Cell and Neural Differentiation: In human embryonic stem cells, Dorsomorphin promotes neural induction and self-renewal by inhibiting BMP/Smad signaling—enabling generation of neural precursors with high efficiency and reproducibility. This application is extended in Strategic Modulation of Cellular Metabolism and Differentiation, which details how Dorsomorphin enables precise manipulation of fate decisions.
• Iron Metabolism Modulation: Animal studies confirm that Dorsomorphin efficiently reduces hepatic hepcidin transcription, resulting in increased serum iron. This property is instrumental for modeling disorders of iron overload or deficiency.
• Autophagy and Redox Signaling: Given the intricate interplay between AMPK, autophagy, and redox-sensitive transcription factors like Nrf2, Dorsomorphin provides a means to dissect how energy sensing intersects with oxidative defense. For instance, the study by Patra et al. explores how cellular stress, Nrf2 regulation, and autophagic processes converge in viral infection models—a context where Dorsomorphin can help parse mechanistic layers.

These advanced applications are further amplified by APExBIO’s rigorous quality control and batch-to-batch consistency, as highlighted in scenario-driven guides such as Practical Solutions for AMPK & BMP Pathway Research, which complements this article by offering real-world troubleshooting and protocol optimization strategies.

Comparative Advantages Over Alternative Inhibitors

• High Selectivity: Dorsomorphin’s selectivity profile minimizes off-target effects, reducing confounding variables in metabolic and differentiation assays.
• Dual-Pathway Targeting: Unlike single-pathway inhibitors, Dorsomorphin enables interrogation of AMPK and BMP/Smad cross-talk, facilitating studies that require simultaneous modulation.
• Reproducibility: APExBIO’s formulation ensures consistent efficacy, as demonstrated in Reproducible AMPK/BMP Assays, which extends this narrative by detailing how Dorsomorphin outperforms less selective or less stable alternatives.

Troubleshooting and Optimization Tips

1. Solubility and Handling

• Always dissolve in DMSO with gentle warming and sonication; avoid water and ethanol. Pre-aliquot stocks to minimize freeze-thaw cycles.
• For cell-based assays, ensure final DMSO concentration is ≤0.1% to avoid solvent toxicity.

2. Dose Selection and Cytotoxicity

• Start with a dose-response curve (4–40 μM in vitro) to identify the minimal effective concentration for pathway inhibition without overt cytotoxicity. For animal studies, do not exceed 10 mg/kg unless justified by pilot data.
• If cytotoxicity is observed, lower the concentration or reduce exposure time. Validate pathway inhibition at each step.

3. Data Interpretation: Off-Target Considerations

• Though highly selective, Dorsomorphin may weakly inhibit other kinases at high concentrations. Always include appropriate controls (e.g., vehicle, non-targeting inhibitors) and verify pathway modulation by multiple readouts (e.g., ACC phosphorylation, phospho-SMAD levels).

4. Workflow Integration

• For combined metabolic and differentiation studies, stagger Dorsomorphin application to parse temporal effects on AMPK versus BMP/Smad pathways.
• Consult scenario-driven guides like Robust Solutions for AMPK & BMP Assays, which extends this troubleshooting framework by mapping common pitfalls and solution strategies.

Future Outlook: Expanding Frontiers in Pathway Modulation

As the intersection between metabolism, autophagy, and cell fate becomes central to disease modeling and therapeutic discovery, Dorsomorphin (Compound C) continues to unlock new investigative avenues. Future directions include:

• Integration with Omics Technologies: Combining Dorsomorphin-based pathway modulation with transcriptomics, proteomics, and metabolomics will clarify downstream effects and reveal novel regulatory nodes.
• Personalized Disease Models: Use in iPSC-derived organoids and patient-specific stem cell models will enable precision targeting of metabolic and differentiation defects—particularly relevant in neurodegeneration, cancer, and rare metabolic disorders.
• Cross-Pathway Synergy Mapping: Co-inhibition or sequential modulation with other pathway inhibitors will help dissect feedback and compensatory mechanisms, refining our understanding of cellular stress responses as outlined in the referenced Nrf2 and redox defense study.

With APExBIO’s commitment to quality and innovation, Dorsomorphin remains a cornerstone for reliable, high-impact research in the life sciences. For detailed product specifications and ordering, visit the Dorsomorphin (Compound C) product page.